

Akronym/Firma	Substanz	Phase	Indikation	Beschreibung	Rekrutierung
<u>IPF und PF-ILD STUDIEN</u>					
ZEPHYRUS/ Fibrogen	Pamrevlumab (FGCL-3019-095)	III	Idiopathische Lungenfibrose	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF).	Aktiv
CSL312_2002/ CSL Behring	CSL312_2002	IIa	Idiopathische Lungenfibrose	A randomized, Double-blind, Placebo-controlled, Study to investigate the Safety, Pharmacokinetics and Pharmacodynamics of CSL312 in Subjects with idiopathic Pulmonary Fibrosis.	Aktiv
HZNP-HZN-825-303/ Horizon	HZN-825	IIb	Idiopathische Lungenfibrose	A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis.	In Vorbereitung
INSMED/ Insmmed Incorporated	INS1009-211 (Treprostinil Palmitil)	II	PF-ILD	A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease.	Aktiv
FIBRONEER/ Boehringer-Ingelheim	BI 1015550	III	Idiopathische Lungenfibrose / PF-ILD	A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over 53'2 weeks in patients with IPF / Progressive Fibrosing Interstitial Lung Disease (PF-ILD).	Aktiv

Alveolar Proteinose STUDIEN

IMPALA 2/ Savara	Molgramostin (GM-CSF inhalativ)	III	Alveolar Proteinose	A randomized, Double Blind, Placebo-controlled Clinical trial of once-daily inhaled Molgramostim nebulizer solution in adult subjects with autoimmune Alveolar-Proteinosis (aPAP).	Aktiv
---------------------	---------------------------------------	-----	------------------------	--	-------

Sarkoidose STUDIEN

CCMK389X2201/ Novartis	CMK389	II	Sarkoidose	A subject and investigator blinded, randomized, placebocontrolled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis.	Aktiv
---------------------------	--------	----	------------	---	-------

Beobachtungsstudien / Registerstudien

INREAL / Alcedis	NIS 1199-0449	NA	Idiopathische Lungenfibrose	Prospective observational investigation of possible correlations between change in FVC and change in cough or dyspnea scores using the living with pulmonary fibrosis questionnaire (L-PF) between baseline and after approximately 52 weeks of nintedanib treatment in patient suffering from chronic fibrosing ILD with a progressive phenotype.	Aktiv
IMPACT / Boehringer-Ingelheim	1465-0008	NA	Idiopathische Lungenfibrose	A multi-center, real-world exploratory cohort study to evaluate cough frequency, severity, and impact on quality of life in patients with non idiopathic pulmonary fibrosis interstitial lung disease	Aktiv
Insight-ILD / Boehringer-Ingelheim / GWD	INSIGHTS-ILD Register	NA	Idiopathische Lungenfibrose	INvestigating SIGnificant Health TrendS in Progressive Fibrosing Interstitial Lung Disease	Aktiv